https://www.bioworld.com/rss en-us http://www.bioworld.com/articles/731189 Wed, 20 May 2026 09:00:00 -0400 https://www.bioworld.com/articles/731189-beijing-tide-pharmaceutical-synthesizes-new-angiotensin-at2-antagonists http://www.bioworld.com/articles/731149 Mon, 18 May 2026 09:00:00 -0400 https://www.bioworld.com/articles/731149-neurolambda-therapeutics-patents-new-tyk2-inhibitors http://www.bioworld.com/articles/731138 Mon, 18 May 2026 09:00:00 -0400 https://www.bioworld.com/articles/731138-aav-encoded-dimeric-pick1-inhibitors-reduce-inflammatory-neuropathic-pain-in-mice http://www.bioworld.com/articles/731120 Fri, 15 May 2026 09:00:00 -0400 https://www.bioworld.com/articles/731120-ksi-028-suppresses-sting-driven-inflammation http://www.bioworld.com/articles/731086 Wed, 13 May 2026 09:00:00 -0400 https://www.bioworld.com/articles/731086-aeovian-pharmaceuticals-synthesizes-new-cd38-inhibitors http://www.bioworld.com/articles/731077 Wed, 13 May 2026 09:00:00 -0400 https://www.bioworld.com/articles/731077-boehringer-ingelheim-licenses-immunitas-antibody-program 3D illustration antibody http://www.bioworld.com/articles/731074 Wed, 13 May 2026 09:00:00 -0400 https://www.bioworld.com/articles/731074-aop-health-and-vrg-therapeutics-partner-on-immunology-program Scientist, microscope and dropper http://www.bioworld.com/articles/730980 Fri, 08 May 2026 12:00:00 -0400 https://www.bioworld.com/articles/730980-odysseys-ipo-placement-brings-304m-to-lead-drugs-in-ibd-lupus IPO, coins, financial chart http://www.bioworld.com/articles/730861 Wed, 06 May 2026 12:00:00 -0400 https://www.bioworld.com/articles/730861-abdakibart-phase-ii-graded-puts-avalo-in-hs-upper-class Hand held near armpit a]pyridine derivatives acting as tyrosine-protein kinase JAK1 inhibitors.]]> http://www.bioworld.com/articles/730915 Wed, 06 May 2026 09:00:00 -0400 https://www.bioworld.com/articles/730915-korea-research-institute-of-chemical-technology-reports-new-jak1-inhibitors http://www.bioworld.com/articles/730902 Wed, 06 May 2026 09:00:00 -0400 https://www.bioworld.com/articles/730902-eyes-are-first-prize-for-newco-link-biologics Rays of light beaming from eye http://www.bioworld.com/articles/730882 Tue, 05 May 2026 09:00:00 -0400 https://www.bioworld.com/articles/730882-evotec-and-almirall-derm-alliance-yields-development-candidate Illustration showing skin anatomy http://www.bioworld.com/articles/730805 Thu, 30 Apr 2026 09:00:00 -0400 https://www.bioworld.com/articles/730805-tmem175-activators-reported-in-ono-pharmaceutical-patent http://www.bioworld.com/articles/730794 Thu, 30 Apr 2026 09:00:00 -0400 https://www.bioworld.com/articles/730794-eq-504-is-ahr-agonist-for-ulcerative-colitis-related-disorders http://www.bioworld.com/articles/730790 Thu, 30 Apr 2026 09:00:00 -0400 https://www.bioworld.com/articles/730790-quintuple-glp-1gipppar-agonist-for-obesity-and-diabetes-control Glucagon-like peptide-1 receptor (GLP-1R) complex Glucagon-like peptide-1 receptor (GLP-1R) complex, representing the molecular target for GLP-1 agonists. Detailed view of the binding site with small-molecule agonist. http://www.bioworld.com/articles/730768 Wed, 29 Apr 2026 09:00:00 -0400 https://www.bioworld.com/articles/730768-foshan-ionova-biotherapeutics-identifies-new-il-17a-inhibitors http://www.bioworld.com/articles/730743 Wed, 29 Apr 2026 09:00:00 -0400 https://www.bioworld.com/articles/730743-montais-mtai-1025-demonstrates-efficacy-in-ulcerative-colitis Illustration of intestines with inflammation http://www.bioworld.com/articles/730618 Fri, 24 Apr 2026 12:00:00 -0400 https://www.bioworld.com/articles/730618-anaptysbios-spinout-first-tracks-hits-the-slopes Drug R&D concept image. http://www.bioworld.com/articles/730569 Wed, 22 Apr 2026 09:00:00 -0400 https://www.bioworld.com/articles/730569-jiangsu-vcare-pharmatech-identifies-new-il-17a-inhibitors BioWorld. Remedy is taking a secretome-based approach to treat lung disorders, having moved its lead asset, RC-0315, into a first-in-human clinical trial for idiopathic pulmonary fibrosis (IPF) in January. ]]> http://www.bioworld.com/articles/730576 Tue, 21 Apr 2026 12:00:00 -0400 https://www.bioworld.com/articles/730576-remedy-pushes-cell-free-secretome-therapy-for-ipf-into-phase-i Ayele Dilion Mashiah, CEO, Remedy Ayelet Dilion Mashiah, CEO, Remedy Cell Ltd. N-formyl peptide receptor 2 (FPR2; FPRL1; LXA4) agonists potentially useful for the treatment of chronic inflammation.]]> http://www.bioworld.com/articles/730462 Fri, 17 Apr 2026 09:00:00 -0400 https://www.bioworld.com/articles/730462-resother-pharma-synthesizes-new-fpr2-agonists a]pyrimidine derivatives acting as adenosine A3 receptor antagonists potentially useful for the treatment of ulcerative colitis, atopic dermatitis, glaucoma, asthma, liver fibrosis, renal disorders, hearing loss and glioblastoma, among others.]]> http://www.bioworld.com/articles/730438 Thu, 16 Apr 2026 09:00:00 -0400 https://www.bioworld.com/articles/730438-perha-pharmaceuticals-identifies-new-adenosine-a3-receptor-antagonists BioWorld. Remedy is taking a secretome-based approach to treat lung disorders, having moved its lead asset, RC-0315, into a first-in-human clinical trial for idiopathic pulmonary fibrosis (IPF) in January. Secretomes refer to the collection of bioactive molecules secreted by cells in the extracellular space, including proteins, enzymes, growth factors and extracellular vesicles such as exosomes.]]> http://www.bioworld.com/articles/730310 Wed, 15 Apr 2026 12:00:00 -0400 https://www.bioworld.com/articles/730310-remedy-pushes-cell-free-secretome-therapy-for-ipf-into-phase-i Ayele Dilion Mashiah, CEO, Remedy Ayelet Dilion Mashiah, CEO, Remedy Cell Ltd. http://www.bioworld.com/articles/730280 Mon, 13 Apr 2026 12:00:00 -0400 https://www.bioworld.com/articles/730280-spyres-spy-001-induces-better-outcomes-in-ulcerative-colitis Ulcerative colitis http://www.bioworld.com/articles/730262 Fri, 10 Apr 2026 09:00:00 -0400 https://www.bioworld.com/articles/730262-tipe2-silencing-attenuates-colitis Gastrointestinal system http://www.bioworld.com/articles/730258 Fri, 10 Apr 2026 09:00:00 -0400 https://www.bioworld.com/articles/730258-dxp-006-reduces-disease-severity-in-psoriasis-models Doctor holding illustration of cross section of skin http://www.bioworld.com/articles/730250 Thu, 09 Apr 2026 09:00:00 -0400 https://www.bioworld.com/articles/730250-leonabio-discovers-new-pannexin-1-inhibitors http://www.bioworld.com/articles/730244 Thu, 09 Apr 2026 09:00:00 -0400 https://www.bioworld.com/articles/730244-lcc-6-characterized-as-an-antifibrotic-and-copper-chelator-agent Photo of pipette with test tube http://www.bioworld.com/articles/730239 Thu, 09 Apr 2026 09:00:00 -0400 https://www.bioworld.com/articles/730239-milestone-under-cue-and-boehringer-ingelheim-collaboration Illustration of lymphocytes http://www.bioworld.com/articles/730201 Wed, 08 Apr 2026 09:00:00 -0400 https://www.bioworld.com/articles/730201-forward-therapeutics-patents-new-tnf-inhibitors